Quality of Life in SMA Patients Under Treatment With Nusinersen

Quality of Life in SMA Patients Under Treatment With Nusinersen

Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease...

Full description

Bibliographic Details
Main Authors: Lucas Mix, Benedikt Winter, Claudia D. Wurster, Sophia Platen, Simon Witzel, Zeljko Uzelac, Heiko Graf, Albert C. Ludolph, Dorothée Lulé
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Neurology
Subjects:
patient reported outcome
spinal muscular atrophy
antisense oligonucleotide
nusinersen (Spinraza)
quality of life
depressiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.626787/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.626787/full

Similar Items